What can be expected from the prostate cancer market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 228-page report provides 213 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole prostate cancer therapeutics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2016-2026 and other analyses show you commercial prospects Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
The report also includes revenue forecasts to 2026 for the following submarkets in the prostate cancer market: • Prostate Cancer Drugs – including revenue forecasts to 2026 for: • Zytiga • Xtandi • Leuplin • Lupron • Jevtana • Zoladex • Casodex • Xofigo • Taxotere
• Prostate Cancer Devices – including revenue forecasts to 2026 for: • Radical Prostatectomy • External Beam Radiation Therapy • Brachytherapy • High-Intensity Focused Ultrasound (HIFU) • Cryotherapy
The report also includes revenue forecasts to 2026 for the following national and regional markets for prostate cancer: • US • Germany • France • Italy • Spain • UK • Japan • China • India • Russia • Brazil • South Korea
The report provides detailed profiles of key companies operating within the prostate cancer market: • Johnson & Johnson • AstraZeneca • Sanofi • AbbVie • Varian Medical Systems • Elekta • Theragenics
Leading companies and potential for market growth Overall revenue for the prostate cancer market will reach $12.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in prostate cancer devices, treatments with more favourable side effect profiles and the launch of several new therapies in both early and late stage prostate cancer will drive sales to 2026.
Our work analyses the key companies in the market. See Visiongain’s analysis of 7 leading companies, including these: • Johnson & Johnson • AstraZeneca • Sanofi • AbbVie • Varian Medical Systems • Elekta • Theragenics
A company profile gives you the following information where available: • Discussion of a company’s activities and outlook • Historic revenue, analysis and discussion of company performance over the past 5 years (where available) • Analysis of major products currently on the market • Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the prostate cancer therapeutics industry? Our new report discusses issues and events affecting the prostate cancer therapeutics market. You will find discussions, including qualitative analyses: • Highly diverse market needing strong knowledge of key therapeutic indications • Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Prostate Cancer Market 2016-2026 report helps you In summary, our 228-page report gives you the following knowledge: • Revenue forecasts to 2026 for the Prostate Cancer market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2026 for each major submarket – discover prospects for leading prostate cancer products in the following areas: prostate cancer drugs and prostate cancer devices. • Revenue forecasts to 2026 for 9 leading drugs – discover prospects for leading prostate cancer drugs including: Zytiga, Xtandi, Leuplin, Lupron, Jevtana, Zoladex, Casodex, Xofigo and Taxotere • Revenue forecasts to 2026 for 5 leading device markets – discover prospects for leading prostate cancer device including: Radical Prostatectomy, External Beam Radiation Therapy, Brachytherapy, High-Intensity Focused Ultrasound (HIFU) and Cryotherapy devices • Revenue forecasts to 2026 for twelve leading national markets – US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea • Assessment of 7 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region and products • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the prostate cancer market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1. The Prostate Cancer Therapeutics Market Overview 1.2. Prostate Cancer Therapeutics Market Segmentation 1.3. Why You Should Read This Report 1.4. How This Report Delivers 1.5. Key Questions Answered by This Analytical Report 1.6. Who is This Report For? 1.7. Methodology 1.8. Frequently Asked Questions (FAQ) 1.9. Associated Reports 1.10. About Visiongain
2. Introduction to Prostate Cancer 2.1. What Is Cancer? 2.2. Phenotypic Characteristics of Cancer Cells 2.2.1. Uncontrolled Growth 2.2.2. Loss of Functioning Apoptotic Pathways 2.2.3. Lack of Differentiation 2.2.4. Increased Angiogenesis 2.2.5. Potential for Metastasis 2.2.6. Genetic Instability 2.3. What Causes Cancer? 2.3.1. Worldwide Prevalence of Cancer: A Global Picture 2.4. What is Prostate Cancer? 2.4.1. Worldwide Prevalence of Prostate Cancer: Rapid Global Growth 2.4.2. Risk Factors for Prostate Cancer 2.5. How is Prostate Cancer Diagnosed? 2.5.1. PSA Testing 2.5.2. Digital Rectal Examination Testing 2.5.3. Prostate Cancer Screening: Does the Cost Justify the Means? 2.5.4. Alternative Tests Could Change Diagnostics 2.6. Treating Prostate Cancer 2.6.1. Localised Prostate Cancer: Surgery/Radiation is Most Preferred 2.6.1.1. Brachytherapy 2.6.1.2. Radical Prostatectomy 2.6.1.3. External Beam Radiation Therapy 2.6.1.4. Cryotherapy 2.6.1.5. High-Intensity Focused Ultrasound (HIFU) 2.6.2. Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy 2.6.3. Non-Metastatic CRPC: Ketoconazole and Anti-Androgens 2.6.4. Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm 2.6.5. First Line Chemotherapy: Docetaxel is a Standard Treatment 2.6.6. Post Docetaxel Therapy: Five FDA Approved Drugs 2.6.7. Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2016-2026 3.1. The Global Prostate Cancer Therapeutics Market, 2014 3.2. The Global Prostate Cancer Therapeutics Market Forecast, 2016-2026 3.3. The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2016-2026
5. The Prostate Cancer Devices Market, 2016-2026 5.1. The Prostate Cancer Devices Market 2014 5.2. The Prostate Cancer Devices Market Forecast, 2016-2026 5.3. The Market Shares of Leading Prostate Cancer Devices Submarkets, 2016-2026 5.4. The Radical Prostatectomy Market 2016-2026 5.4.1. Intuitive Surgical’s da Vinci Surgical System 5.5. The External Beam Radiation Therapy Market, 2016-2026 5.6. The Brachytherapy Market 2016-2026 5.7. The Cryotherapy Market 2016-2026 5.8. The HIFU Market, 2016-2026
6. The Leading Companies in the Prostate Cancer Therapies Market, 2016 6.1. The Leading Companies in the Prostate Cancer Drugs Market, 2016 6.2. Johnson & Johnson (J&J) 6.2.1. Sales and Performance Analysis, 2015 6.2.2. Pharmaceutical Segment Sales Analysis, 2015 6.2.3. Oncology Drugs Sales and Performance Analysis, 2015 6.2.4. Pharmaceutical Segment R&D Performance Analysis, 2015 6.2.5. Acquisition of Aragon Pharmaceuticals 6.3. AstraZeneca 6.3.1. Sales and Performance Analysis, 2015 6.3.2. Pharmaceutical Segment Sales & R&D Analysis by Segment, 2015 6.3.3. Oncology Drugs Sales and Performance Analysis, 2015 6.4. Sanofi 6.4.1. Sales and Performance Analysis, 2015 6.4.2. Sales and Performance Analysis by Segment, 2015 6.4.3. Oncology Sales and Performance Analysis, 2015 6.4.4. R&D Performance Analysis, 2015 6.4.5. Oncology Pipeline Portfolio 6.5. AbbVie 6.5.1. Sales and Performance Analysis, 2015 6.5.2. R&D Performance Analysis, 2015 6.5.3. Humira: From “First-In-Class” to “Best-In-Class”, 2015 6.5.4. Oncology Portfolio Pipeline Products, 2015 6.6. Leading Companies in the Prostate Cancer Devices Market 2016-2026 6.7. Varian Medical Systems 6.7.1. Sales and Performance Analysis, 2015 6.7.2. Oncology Segment Sales Analysis, 2015 6.7.3. Sales Analysis by Region, 2015 6.7.4. R&D Performance Analysis, 2015 6.7.5. Key Oncology Products, 2015 6.7.6. Varian and Siemens Partnership: Shaping the Future of Cancer Care 6.8. Elekta 6.8.1. Sales and Performance Analysis, 2015 6.8.2. Sales and Performance Analysis by Region, 2015 6.8.3. Elekta and Philips Establish Research Consortium 6.8.4. Product Launch and Development, 2015 6.9. Theragenics Corporation (acquired by Juniper Acquisition Corporation) 6.9.1. Theragenics Sales Performance Analysis, 2014 6.9.2. Theragenics Sales Performance by Operation, 2012 6.9.3. Sales and Performance Analysis by Business Unit, 2012 6.9.4. Mergers and Acquisitions 6.9.4.1. Juniper’s acquisition of Theragenics 6.9.4.2. Acquisition of US & Canadian Seed Business of Eckert & Ziegler BEBIG 6.9.4.3. Acquisition of Needle Tech Products 6.9.4.4. Acquisition of Galt Medical
7. The Leading National Markets, 2016-2026 7.1. Regional Breakdown of the Prostate Cancer Therapeutics Market, 2014 7.2. The Prostate Cancer Therapeutics Market: Regional Forecast, 2016-2026 7.3. Market Shares Forecasts of Leading National Prostate Cancer Therapeutics Markets, 2016-2026 7.4. The US Prostate Cancer Therapeutics Market 2016-2026 7.5. The European Prostate Cancer Therapeutics Market, 2014 7.6. The European Prostate Cancer Therapeutics Market, 2015-2025 7.6.1. The German Prostate Cancer Therapeutics Market, 2016-2026 7.6.2. The French Prostate Cancer Therapeutics Market, 2016-2026 7.6.3. The UK Prostate Cancer Therapeutics Market, 2015-2025 7.6.4. The Spanish Prostate Cancer Therapeutics Market, 2016-2026 7.6.5. The Italian Prostate Cancer Therapeutics Market, 2016-2026 7.7. The Japanese Prostate Cancer Therapeutics Market, 2016-2026 7.8. The Chinese Prostate Cancer Therapeutics Market, 2016-2026 7.9. The Brazilian Prostate Cancer Therapeutics Market, 2016-2026 7.10. The Russian Prostate Cancer Therapeutics Market, 2016-2026 7.11. The Indian Prostate Cancer Therapeutics Market, 2016-2026 7.12. The South Korean Prostate Cancer Therapeutics Market, 2016-2026 7.13. The Rest of the World Prostate Cancer Therapeutics Market, 2016-2026
8. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2016-2026 8.1. SWOT Analysis, 2016-2026 8.2. Strengths 8.2.1. Rapidly Ageing Male Populations Worldwide 8.2.2. A Number of Promising Pipeline Drug Candidates 8.2.3. Successful Partnerships Between Big and Small Pharmaceutical Companies Leading to New Products 8.3. Weaknesses 8.3.1. High Treatment Costs 8.3.2. High Levels of Phase III Attrition 8.4. Opportunities 8.4.1. Rising Incidence of Cancer 8.4.2. Development of Emerging Markets 8.5. Threats 8.5.1. Concerns about Efficacy and Toxicity of Drugs 8.5.2. Increase in Generic Competition 8.5.3. Healthcare Budget Restraints 8.6. Porter’s Five Force Analysis 8.6.1. Rivalry Among Competitors [High] 8.6.2. Threat of New Entrants [High] 8.6.3. Power of Suppliers [Low] 8.6.4. Power of Buyers [High] 8.6.5. Threat of Substitutes [Low]
9. Conclusions 9.1. The Prostate Cancer Therapeutics Market, 2016-2026 9.2. The US Will Remain the Largest National Market from 2016 to 2026 9.3. Concluding Remarks
10. Glossary
Appendix Visiongain’s Bespoke Research Service Some Associated Reports Visiongain Report Sales Order Form About Visiongain Report Evaluation Form
List of Tables Table 1.1 Global Prostate Cancer Therapies Market: Market Forecast ($m, AGR% and CAGR%) by Segment, 2014-2020 (Altered Data) Table 2.1 PSA Testing: Benefits and Limitations, 2016 Table 2.2 New Prostate Cancer Diagnostic Tests in Market, 2015 Table 2.3 Advantages and Disadvantages of Brachytherapy, 2016 Table 2.4 Advantages and Disadvantages of Radical Prostatectomy, 2016 Table 2.5 Advantages and Disadvantages of External Beam Radiation, 2016 Table 2.6 Advantages and Disadvantages of Cryotherapy, 2016 Table 2.7 Advantages and Disadvantages of HIFU, 2016 Table 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Segment, 2014 Table 3.2 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 3.4 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints 2016-2026 Table 4.1 The Prostate Cancer Drugs List: Key Brands, 2015 Table 4.2 The Prostate Cancer Drugs Market: Revenue ($m), Market Share (%) by Leading Drugs, 2015 Table 4.3 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.4 The Prostate Cancer Drugs Market Forecast by Leading Drugs, Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.5 Market Shares (%) of the Leading Prostate Cancer Drugs, 2020 and 2026 Table 4.6 Sanofi: Taxotere Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.7 Sanofi: Taxotere Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.8 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.9 Sanofi: Jevtana Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.10 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.11 AstraZeneca: Casodex Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.12 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2026 Table 4.13 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.14 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.15 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.16 Zoladex (AstraZeneca): Zoladex Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.17 Zoladex (AstraZeneca): Zoladex Prostate Cancer Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.18 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.19 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.20 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.21 Medivation/Astellas: Xtandi Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.22 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.23 Bayer: Xofigo Revenue Forecast ($m), AGR (%) and CAGR (%), 2020-2026 Table 4.24 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2020 Table 4.25 Other Prostate Cancer Drugs: Revenue Forecast ($m), AGR (%) and CAGR (%), 2014-2026 Table 4.26 Key Drugs in Phase III Clinical Trials , 2016 Table 4.27 Key Drugs in Phase II Clinical Trials , 2016 Table 4.28 Key Drugs in Phase I Clinical Trials, 2016 Table 5.1 The Prostate Cancer Devices Market: Revenue ($m) and Market Share (%) by Segment, 2014 Table 5.2 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2014-2020 Table 5.3 The Prostate Cancer Devices Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Segment, 2020-2026 Table 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and Market Shares (%), 2014, 2020 and 2026 Table 5.5 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.6 The Radical Prostatectomy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.7 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.8 The External Beam Radiation Therapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.9 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.10 The Brachytherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.11 The Cryotherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.12 The Cryotherapy Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 5.13 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 5.14 The HIFU Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 6.1 Johnson & Johnson: Revenue ($m) and Revenue Share (%) by Segment, 2015 Table 6.2 Johnson & Johnson: Historical Revenue ($bn), AGR (%) and CAGR (%), 2010-2015 Table 6.3 Johnson & Johnson Pharmaceuticals: Revenue ($bn), and Revenue Shares (%) by Segment, 2015 Table 6.4 Johnson & Johnson Pharmaceuticals: Top 5 Best Selling Drugs, Revenue ($bn) and Revenue Share (%) 2015 Table 6.5 Johnson & Johnson: Oncology Pharmaceuticals Segment: Revenue ($m) and Percentage Share (%) by Drug, 2014-2015 Table 6.6 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2010-2015 Table 6.7 AstraZeneca: Revenue ($bn), AGR (%), 2010-2015 Table 6.8 AstraZeneca: Revenue ($bn), Revenue Shares (%) by Segment, 2015 Table 6.9 AstraZeneca: R&D Expenditure ($bn), Revenue ($bn) and R&D Expenditure as a Percentage of Sales, 2010-2015 Table 6.10 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2015 Table 6.11 AstraZeneca Oncology: Investigational Oncology Compounds in Mid to Late Stage Clinical Trials, 2015 Table 6.12 Sanofi: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015 Table 6.13 Sanofi: Global Sales Revenue ($bn), Percentage Change (%) and Percentage Change at Constant Exchange Rates (%) by Region, 2014-2015 Table 6.14 Sanofi: Sale Revenue ($bn) and Revenue Shares (%) by Segment, 2015 Table 6.15 Sanofi: Revenue ($m) and Revenue Share (%) by Sub-Segments, 2015 Table 6.16 Sanofi: Oncology Sales ($m) and Revenue Share (%) by Product, 2015 Table 6.17 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Revenue (%), 2010-2015 Table 6.18 Sanofi: Major Compounds from Sanofi’s Oncology Pipeline, 2015 Table 6.19 AbbVie: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015 Table 6.20 AbbVie Main Products: Revenue ($m) 2013-2015 Table 6.21 AbbVie: Humira Indications by Regions, 2016 Table 6.22 Varian Medical Systems: Revenue ($bn), AGR (%) and CAGR (%), 2010-2015 Table 6.23 Varian Medical Systems: Revenue ($bn) and Revenue Share (%), 2015 Table 6.24 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Segment, 2015 Table 6.25 Varian Medical Systems: Oncology Systems Revenue ($bn), Revenue Shares (%) by Region, 2015 Table 6.26 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2015 Table 6.27 Elekta: Revenue ($bn), AGR (%) and CAGR (%) 2010-2015 Table 6.28 Elekta: Revenue ($m), by Country 2014-2015 Table 6.29 Theragenics: Revenue ($m), AGR (%) and CAGR (%) 2008-2012 Table 6.30 Theragenics: Revenue ($m) and Revenue Share (%) by Business Unit, 2012 Table 7.1 The Prostate Cancer Therapeutics Market: Revenue ($m) and Market Share (%) by Region, 2014 Table 7.2 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.3 The Leading Prostate Cancer Therapeutics National Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.4 Revenue ($m) and Market Shares (%) of the Leading Prostate Cancer Therapeutics National Markets, 2014, 2020 and 2026 Table 7.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.6 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.7 The European Prostate Cancer Therapeutics Markets: Revenue ($m), Market Share (%) by Country/Region, 2014 Table 7.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.9 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.10 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.11 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.12 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.13 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.14 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.15 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.16 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.17 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.18 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.19 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.20 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.21 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.22 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.23 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.24 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.25 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.26 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.27 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.28 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.29 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.30 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.31 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 7.32 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2020 Table 7.33 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2020-2026 Table 8.1 SWOT Analysis of the Prostate Cancer Therapeutics Market, 2016-2026
List of Figures Figure 1.1 Prostate Cancer Therapeutics: Overview of Submarkets and Segments Figure 2.1 Risk Factors Associated with Cancer Development Figure 2.2 Global Proportion (%) of Newly Diagnosed Cancer by Type (Excluding Non-Melanoma Skin Cancer), 2012 Figure 2.3 Risk Factors Associated with Prostate Cancer Development Figure 2.4 Prostate Cancer Incidence and Mortality in the US per 100,000 people, by Ethnicity, 2007-2011 Figure 2.5 Treatment Sequence for Prostate Cancer, 2016 Figure 3.1 The Global Prostate Cancer Therapeutics Market: Revenue ($m) by Segment, 2014 Figure 3.2 The Global Prostate Cancer Therapeutics Market: Market Share (%) by Segment, 2014 Figure 3.3 The Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 4.1 The Prostate Cancer Drugs Market: Revenue ($m) by Leading Drugs, 2015 Figure 4.2 The Prostate Cancer Drugs Market: Market Share (%) by Leading Drugs, 2015 Figure 4.3 The Prostate Cancer Drugs Market Forecast, Revenue ($m) and AGR (%), 2014-2026 Figure 4.4 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2020 Figure 4.5 The Prostate Cancer Drugs Market: Market Shares (%) by Leading Drug, 2026 Figure 4.6 Taxotere (Sanofi): Taxotere Revenue Forecast ($m) and AGR (%) 2014-2026 Figure 4.7 Sanofi: Jevtana Revenue Forecast ($m) and AGR (%) 2014-2026 Figure 4.8 AstraZeneca: Casodex Revenue Forecast ($m) and AGR (%) 2014-2026 Figure 4.9 Takeda: Leuplin Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026 Figure 4.10 AbbVie: Lupron Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026 Figure 4.11 AstraZeneca: Zoladex Prostate Cancer Revenue Forecast ($m) and AGR (%) 2014-2026 Figure 4.12 Johnson & Johnson: Zytiga Revenue Forecast ($m), AGR (%),2014-2026 Figure 4.13 Medivation/Astellas: Xtandi Revenue Forecast ($m) and AGR (%), 2014-2026 Figure 4.14 Bayer: Xofigo Revenue Forecast ($m) and AGR (%), 2014-2026 Figure 4.15 Other Prostate Cancer Drugs: Revenue Forecast ($m) and AGR (%), 2014-2026 Figure 5.1 Segmentation of the Prostate Cancer Devices Market, 2016 Figure 5.2 The Prostate Cancer Devices Market: Revenue ($m) by Segment, 2014 Figure 5.3 The Prostate Cancer Devices Market: Market Share (%) by Segment, 2014 Figure 5.4 The Prostate Cancer Devices Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.5 The Prostate Cancer Devices Market Segments: Revenue ($m) Forecast, 2014, 2020, 2026 Figure 5.6 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2020 Figure 5.7 The Prostate Cancer Devices Market: Market Shares (%) by Leading Devices Submarkets, 2026 Figure 5.8 The Radical Prostatectomy Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.9 The External Beam Radiation Therapy Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.10 The Brachytherapy Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 5.11 The Cryotherapy Market Forecast: Revenue ($m), AGR (%), 2014-2026 Figure 5.12 The HIFU Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 6.1 Johnson & Johnson: Revenue Shares (%) by Segment, 2014 Figure 6.2 Johnson & Johnson: Historical Revenue ($bn) and AGR (%), 2010-2015 Figure 6.3 Johnson & Johnson Pharmaceuticals: Revenue ($bn) by Segment, 2015 Figure 6.4 Johnson & Johnson Pharmaceuticals: Revenue Share (%) by Segment, 2015 Figure 6.5 Johnson & Johnson Pharmaceuticals: Revenue Shares (%) by Leading Drugs, 2015 Figure 6.6 Johnson & Johnson Oncology Pharmaceuticals Segment: Revenue Share (%) by Drug, 2014 Figure 6.7 Johnson & Johnson: Historical Pharmaceutical R&D Expenses ($bn) and R&D Expenses as Percentage of Company Revenue (%), 2011-2015 Figure 6.8 AstraZeneca: Revenue ($bn), AGR (%), 2010-2015 Figure 6.9 AstraZeneca: Revenue ($bn) by Segment, 2015 Figure 6.10 AstraZeneca: Revenue Shares (%) by Segment, 2015 Figure 6.11 AstraZeneca Performance: R&D Costs ($bn) and Percentage of Sales (%), 2010-2015 Figure 6.12 AstraZeneca: Oncology Drugs Revenue ($m), 2012-2015 Figure 6.13 AstraZeneca: Revenue Share (%) of Oncology Drugs, 2015 Figure 6.14 Sanofi: Historical Revenue ($bn) and AGR (%), 2010-2015 Figure 6.15 Sanofi: Global Sales Revenue ($bn) and Percentage Change (%) by Region, 2014-2015 Figure 6.16 Sanofi: Revenue ($bn) by Segment, 2015 Figure 6.17 Sanofi: Revenue Share (%) by Segment, 2015 Figure 6.18 Sanofi: Pharmaceutical Sub-segment Revenue Share (%), 2015 Figure 6.19 Sanofi: Oncology Revenue ($bn) by Product, 2015 Figure 6.20 Sanofi: Oncology Revenue Share (%) by Product, 2015 Figure 6.21 Sanofi: Historical R&D Expenses ($bn) and R&D Expenses as Percentage of Net Sales (%), 2010-2015 Figure 6.22 AbbVie: Revenue ($bn) and AGR (%), 2010-2015 Figure 6.23 AbbVie Main Products: Revenue ($m) Comparison, 2013-2015 Figure 6.24 AbbVie: Revenue Share (%) by Drug, 2015 Figure 6.25 Varian Medical Systems: Revenue ($bn) and AGR(%), 2010-2015 Figure 6.26 Varian Medical Systems: Revenue ($bn) by Segment, 2015 Figure 6.27 Varian Medical Systems: Revenue Share (%) by Segment, 2015 Figure 6.28 Varian Medical Systems: Oncology Systems Revenue ($bn) by Segment, 2015 Figure 6.29 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Segment, 2015 Figure 6.30 Varian Medical Systems: Oncology Systems Revenue Shares (%) by Region, 2015 Figure 6.31 Varian Medical Systems: Historical R&D Expenses ($m) and R&D Expenses as Percentage of Revenue (%), 2011-2015 Figure 6.32 Elekta: Historical Revenue ($bn) and AGR (%), 2010-2015 Figure 6.33 Elekta: Historical Revenue ($m), by Country 2014-2015 Figure 6.34 Elekta: Revenue Share (%) by Country 2015 Figure 6.35 Theragenics: Revenue ($m) and AGR (%), 2008-2012 Figure 6.36 Theragenics: Revenue Share (%) by Operation, 2012 Figure 6.37 Theragenics: Revenue ($m) by Business Unit, 2012 Figure 6.38 Theragenics: Revenue Share (%) by Business Unit, 2012 Figure 7.1 The Prostate Cancer Therapeutics Market: Revenue ($m) by Region, 2014 Figure 7.2 The Prostate Cancer Therapeutics Market: Market Share (%) by Region, 2014 Figure 7.3 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2020 Figure 7.4 The Prostate Cancer Therapeutics Market: Market Shares (%) by Region, 2026 Figure 7.5 The US Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.6 The European Prostate Cancer Therapeutics Markets: Revenue ($m) by Country / Region, 2014 Figure 7.7 The European Prostate Cancer Therapeutics Markets: Market Share (%) by Country / Region, 2014 Figure 7.8 The European Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%),2014-2026 Figure 7.9 The German Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.10 The French Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2026 Figure 7.11 The UK Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2026 Figure 7.12 The Spanish Prostate Cancer Therapeutics Market Forecast: Revenue ($m), AGR (%), 2014-2026 Figure 7.13 The Italian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.14 The Japanese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.15 The Chinese Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.16 The Brazilian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.17 The Russian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.18 The Indian Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.19 The South Korean Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 7.20 The RoW Prostate Cancer Therapeutics Market Forecast: Revenue ($m) and AGR (%), 2014-2026 Figure 8.1 Porter’s Five Force Analysis of the Prostate Cancer Therapeutics Market, 2016-2026
AbbVie Accord Healthcare Inc. Actavis Advanced Medical Isotope Corporation Advantagene Algeta ASA Almirall Aragon Pharmaceuticals Astellas Pharmacueticals AstraZeneca Bavarian Nordic Bayer Healthcare Bayer Pharmaceuticals Beckman Coulter Bellicum Pharmaceuticals Bostwick Laboratiories Breckenridge Pharmaceuticals Bristol Myers Squibb (BMS) BTG Plc Computer Motion Cougar Biotechnology CR Bard Danaher Corporation Dendreon Eckert & Ziegler BEBIG, S.A EDAP TMS Elekta F. Hoffman-La Roche AG Ferring Pharmaceuticals Galt Medical GenomeDx Biosciences Genomic Health Gen-Probe Genzyme Gilead Science Hologic Hospira Inc. Intuitive Surgical Iris International Johnson & Johnson (J&J) Juniper Acquisition Corporation Juniper Investment Company MDx Health Medivation Metabolon Metamark Genetics Mitomics Mylan Pharmaceuticals Myriad Genetics Needle Tech Products Nucletron OncoGenex Oncura Opko Health Pfizer Philips Progenics Pharmaceuticals Regeneron Sandoz Sanofi Sanofi-Aventis Siemens Healthcare SonaCare Medical Steba Biotech Sython Pharmaceuticals Takeda Teva Pharmaceuticals Theragenics Tokai Pharmaceuticals Tolmar Pharmaceuticals Valeant Pharmaceuticals Varian Medical Systems Zydus Pharmaceuticals
Organisations Mentioned in the Report American Cancer Society Brazilian Pharmaceutical Price Regulation Board (CMED) Cancer Research UK Central Intelligence Agency (CIA) European Partnership Action Against Cancer (EPAAC) GLOBOCAN Indian Brand Equity Foundation (IBEF) International Agency for Research on Cancer (IRAC) Japanese Ministry of Health, Labour, and Welfare (MHLW) Memorial Sloan Kettering Cancer Center Mount Siani Medical Centre (New York) National Cancer Institute National Institute of Clinical Excellence (NICE) Oxford University UK National Health Service (NHS) University of California, Los Angeles (UCLA) US Department of Defence US Food and Drug Agency (FDA) US Preventative Services Task Force (USPSTF) Weizmann Institute World Cancer Research Fund International World Health Organization (WHO) The Froedtert & Medical College of Wisconsin Clinical Cancer Centre University Medical Centre Utrecht (Netherlands) University of Texas MD Anderson Centre (Texas) The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital (Netherlands) Sunnybrook Health Sciences (Ontario)
Download sample pages
Complete the form below to download your free sample pages for The Prostate Cancer Market 2016-2026
Download sample pages
Complete the form below to download your free sample pages for The Prostate Cancer Market 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2021-2031
The potential for digital & analytics applications in the pharmaceutical and biotechnology sector has grown dramatically in recent years as a result of fast technological advances as well as changes in the market environment & stakeholder behaviour as a result of the pandemic.
The rising prevalence of oncological disorders, lung infections, rising demand for customised drugs coupled with new orphan diseases discoveries, are few of the major reasons responsible for development of pharmaceutical spray drying market.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
